The costs of washed autologous red cell concentrate obtained by intraoperative red cell salvage were compared to the costs of allogeneic packed red cell transfusion during 110 consecutive abdominal aortic aneurysm repairs. The mean volume of scavenged blood during elective procedures was 1350 ml (range 350 to 6675 ml, n=90) and emergency procedures 2750 ml (range 750 to 9400 ml, n=20). The mean volume of processed (washed) blood returned during elective repairs was 759 ml (range 150 to 2900 ml, n=51) and emergency repairs 1117 ml (range 0 to 4100 ml, n=20). During elective repairs, the cost of routine autologous red cell salvage ($151 per 285 ml unit) was only slightly greater than the estimated cost of cross-matched, leucocyte-reduced, allogeneic blood ($143 per 285 ml unit). During emergency repairs, washed autologous red cells ($83 per 285 ml unit) were less expensive than allogeneic packed red cells. These findings indicate that, compared with the use of allogeneic packed red cells, red cell salvage during emergency abdominal aortic aneurysm repair can be justified on an economic basis alone, and that routine red cell salvage during elective repair can achieve the benefits of autologous blood at little extra cost to the community.
Autologous red cell concentrate obtained by intraoperative red blood cell salvage has many advantages over its allogeneic packed red cell equivalent 1 . However, because the risks of allogeneic blood transfusion are low 2 , the additional costs of autologous blood may be difficult to justify 3 . The costs of intraoperative autologous red cell salvage are related to the costs of the disposable equipment required to collect and process (wash) scavenged blood and to the labour costs associated with running the cell salvage device. Allogeneic blood also has its costs which are incurred during donor blood collection, blood typing, screening for antibodies and screening for infectious agents. Little current information is available on the relative costs of these alternative sources of blood, especially in Australia. The aim of the current study was to compare the costs of autologous red cell salvage and allogeneic red cell transfusion during infrarenal abdominal aortic aneurysm (AAA) repair. To ensure that no bias was introduced, the study was completed without external support of any kind.
METHODS
The study was carried out in a public teaching hospital over three years commencing September 1995. During this period, shed blood was scavenged during all infrarenal AAA repairs into disposable reservoirs (EL240, Medtronics, Parker, CO, U.S.A.). Each reservoir was primed with normal saline 200 ml to which heparin 3IU.ml -1 was added. Subsequent anticoagulation was achieved by the continous delivery of heparin 3IU.ml -1 to the patient end of the suction tubing (BTC93, Medtronics, Parker, CO, U.S.A.) at a rate of approximately 10 ml per 90 ml of scavenged blood. The suction pressure was limited to -60 mmHg to minimize haemolysis. No additional personnel were required for scavenging of shed blood.
The decision to commence processing of scavenged blood using the cell saver (AT1000, Electromedics, Eaglewood, CO, U.S.A.) for elective cases depended on the rate and the amount of blood loss and the stage of the procedure, but usually required a minimum of 1000 ml of scavenged blood. For emergency cases, the cell salvage device was set up to process scavenged blood routinely. The scavenged blood was processed using a 125 ml bowl (EC1524, Medtronics, Parker, CO, U.S.A.) and centrifugation at 5600 rpm. Processing of scavenged blood required an additional anaesthesia technician for approximately three hours to run the cell saver device.
Prospective data collection included the volume of blood scavenged, the volume of processed blood that was returned to the patient and the haematocrit of the processed blood.
The costs of autologous blood were estimated by dividing the total volume of autologous blood returned to patients by the total costs of blood scavenged (disposable equipment plus labour whether blood was processed or not), and the costs of processing shed blood when this was undertaken.
Information on costs of allogeneic packed red cells were obtained from the Australian Red Cross Blood Service. The costs of cross-matching allogeneic blood were estimated using the Australian Government Medicare Benefits Schedule 4 .
RESULTS
One hundred and ten consecutive patients undergoing infrarenal AAA repair were studied. Of these, 90 were undergoing elective repair and 20 emergency repair. There was sufficient scavenged blood for processing in 51 (56%) of the elective repairs and 15 (75%) of the emergency repairs. The mean age of the patients undergoing elective repair was 72.6 y (range 51 to 86 y), and emergency repair 71.9 y (range 58 to 84 y). The mean haematocrit of the autologous red cell concentrate was 0.60 (range 0.49 to 0.69), which is similar to the haematocrit of allogeneic packed red cells.
All cost information is based on 1999 figures and is presented in Australian dollars.
The average per patient cost of the disposables to scavenge shed blood was approximately $135.00, and to process shed blood a further $115.00. The additional labour costs to process the shed blood were $17.00 per hour for elective cases and $25.00 per hour for after hours emergency cases.
No figures for the costs of individual units of allogeneic blood are published by the Australian Red Cross Blood Service. However, the approximate recurrent cost for providing one unit of allogeneic packed red cells (285 ml) has been estimated to be at least $100.00 (Red Cross Blood Service, personal communication).
The Medicare Benefits Schedule fee for crossmatching up to six units of allogeneic blood on any single day is $110.00. Therefore, we estimated the cost of crossmatching allogeneic blood as $18.00 per unit. The cost of a leucocyte-reduction filter (Purecell, Pall Biomedical, Portsmouth, U.K.) is currently $25.00.
The autologous red blood cell salvage data is given in Table 1 . The cost comparison is given in 
DISCUSSION
The results of this study indicate that the cost of autologous red blood cell salvage during infrarenal AAA repair compares favourably with the cost of allogeneic packed red cell transfusion. For emergency repairs, the cost of autologous red cell concentrate represents a cost saving compared to the cost of allogeneic packed red cells, especially if the costs of crossmatching or leucocyte reduction are added ( Table 2 ). For elective repairs the cost of autologous red cell concentrate is only slightly greater than the cost of crossmatched, leucocyte-reduced allogeneic blood (Table 2) . Therefore, for infrarenal AAA repair, intraoperative autologous red cell salvage can be justified on an economic basis alone.
Abdominal aortic aneurysm repair is one of the most common indications for intraoperative autologous red cell salvage 1 . It is invariably associated with significant blood loss, and the shed blood tends to pool within the operative site allowing suctioning with minimal air-fluid interface. Moreover, there are no contraindications to red cell salvage during AAA repair, such as contamination with bowel contents or tumour cells. Alternatives such as autologous predonation are often not possible, even for elective cases, due to patient co-morbidities. Despite this, there have been few studies that have examined the cost-efficacy of autologous red cell salvage during AAA repair.
The cost-efficacy of intraoperative autologous red cell salvage is heavily influenced by the amount of blood loss. It has been suggested that a minimum of 1000 ml of scavenged blood is required to return one unit of washed autologous red cell concentrate 5 . If this threshold is not reached, the disposables used for collection are wasted. On the other hand, once the decision to process shed blood is made, the disposable equipment costs are fixed, irrespective of the amount of blood loss. In this way the greater the blood loss, the cheaper the cost of the red cells saved. Our figures for scavenged blood during AAA repair are similar to or less than figures previously reported by several other investigators, and may be considered conservative for the procedure [6] [7] [8] . However, for accurate information, each institution should analyse their own blood loss data and perform their own cost analysis.
Although the results apply primarily to infrarenal AAA repairs, it may be possible to extrapolate the findings to other procedures. Intraoperative autologous red cell salvage for procedures with a lower average blood loss will be relatively more expensive. In contrast, intraoperative red cell salvage for pro-cedures with a higher average blood loss will be relatively less expensive or even provide a cost saving.
The transfusion of allogeneic leucocytes has been implicated in causing immunosuppression and transmission of infection 10, 11 . Transfusion-related immunosuppression may be associated with a higher incidence of both postoperative infection and tumour recurrence 10 . At present, only a small proportion of allogeneic blood in Australia is leucocyte-reduced. This is in contrast to the United Kingdom and many other countries which have made the decision to leucocyte-reduce all allogeneic red cell products 9 . It is likely that Australia will follow the overseas example and leucocyte-reduce all, or a larger percentage of allogeneic red cell products in future. The New Zealand Blood Service has already committed to leucocyte-reduce all allogeneic red cell products by the end of the year 2000 (personal communication). Whether leucocyte-reduction takes place at source or at point of care, additional disposable single-use filters are required. Autologous blood requires no such filters. Therefore, for an appropriate comparison, the costs of a leucocyte-reduction filter should be added to the cost of allogeneic blood.
The current Medicare Benefits Schedule fee for crossmatching one to six units of allogeneic blood on any single day is $110.00 4 . Allogeneic blood is usually cross-matched on the day before surgery in order to be available on the morning of surgery. If additional crossmatching is required on the day of surgery, or if the total amount exceeds six units, there are additional pathology charges 4 . The use of intraoperative cell salvage reduces the likelihood of requiring additional crossmatching. In this way, there is a further cost saving associated with using cell salvage.
Although the costs used in this study apply primarily to our own institution, it is likely that other public institutions within Australia will have similar costs. The costs of the disposable equipment are similar throughout Australia, and the labour costs, which may vary slightly from institution to institution, are a small component of the total. In the same way, different red cell salvage devices have similar costs for disposables. However, the findings do not apply to private institutions or organizations whose charges contain a profit component.
One criticism of this study could be the lack of hard data on the costs of allogeneic blood for comparison purposes. The Australian Red Cross Blood Service does not report or publish its costs per unit of blood, because these are extremely difficult to determine. Nevertheless, each unit of allogeneic blood requires collection from a screened donor, blood typing and screening for abnormal antibodies, and screening for infective agents (including hepatitis B, C, and human immunodeficiency virus) before it is made available to individual hospitals. To provide this service requires substantial recurrent costs such that the figure of $100.00 per unit may be a conservative estimate. Substantially higher costs for allogeneic blood have been reported from Italy ($163.00 per unit) 12 , and the United States ($195.00 per unit) 13 . In some countries, payments to blood donors would further increase costs. These costs must be borne by the community, although in Australia at present, allogeneic blood is provided free to hospitals and patients.
In contrast to the costs of allogeneic blood, the costs of intraoperative autologous red cell salvage are usually met directly by hospitals. Therefore, individual departments or hospitals may have a financial incentive to use allogeneic rather than autologous products. Clinicians should resist making clinical decisions based on political issues of this type. Rather they should act in the best interest of their patients and alert funding authorities to recoup costs where appropriate.
In this study, only recurrent costs have been assessed. The costs of purchase, lease or depreciation of the cell salvage device have not been included in the cost of the autologous red cell concentrate. Similarly, the infrastructure costs of the Australian Red Cross Blood Service have not been included in this estimate of the cost of allogeneic blood.
The aim of this study was to compare costs only and not benefits. Nevertheless, there are substantial benefits to the use of autologous rather than allogeneic blood 1 . Most patients prefer to avoid allogeneic blood products where possible, even though the risk of adverse reaction is low 2 . Fresh autologous red cells are also a better product than allogeneic red cells because they do not have a storage lesion 1 . Moreover, the use of autologous blood facilitates the conservation of a resource that is becoming increas-ingly scarce. It is hard to place a dollar value on these benefits, which makes a cost-benefit analysis all the more difficult to perform. Our study suggests that for AAA repairs, and other procedures with similar (or greater) blood loss, the benefits of autologous blood can be attained with little or no increased cost.
